Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
236.65(c) 236.5(c) 235.05(c) 235.15(c) 233(c) Last
1 232 872 1 280 267 1 712 515 4 042 096 1 328 760 Volume
-0.17% -0.06% -0.61% +0.04% -0.91% Change
More quotes
Financials (CHF)
Sales 2018 56 475 M
EBIT 2018 19 233 M
Net income 2018 12 946 M
Debt 2018 4 708 M
Yield 2018 3,74%
Sales 2019 57 588 M
EBIT 2019 19 292 M
Net income 2019 13 126 M
Debt 2019 66,2 M
Yield 2019 3,77%
P/E ratio 2018 15,54
P/E ratio 2019 15,24
EV / Sales2018 3,67x
EV / Sales2019 3,52x
Capitalization 203 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
09/24 | 04:30pmPresentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
09/24GENENTECH : ’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based..
BU
09/24GENENTECH : ’s Investigational Medicine Entrectinib Showed a Durable Respo..
BU
09/21AbbVie Gets Positive CHMP Opinion for Combination of Venclyxto With Rituximab..
DJ
09/13Roche Works to Fill Sales Gap as Biosimilars Emerge -Reuters
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Syste..
BU
09/13ROCHE : boss says Brexit and curbs on drug use pose threat to UK science
RE
09/10U.K. Health Regulator Rejects Roche's MS Drug
DJ
09/10ROCHE : faces UK pricing row over multiple sclerosis drug Ocrevus
RE
09/06FDA Extends Review Period for Roche Cancer Treatment License
DJ
More news
Sector news : Pharmaceuticals - NEC
09/24ASTRAZENECA : EU Grants Marketing Authorization to AstraZeneca's Imfinzi
DJ
09/24ALEXION PHARMACEUTICALS : Soliris Meets Main Endpoint in Central Nervous System ..
DJ
09/24ASTRAZENECA : Mixed Results from Farxiga Trial
DJ
09/24SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/24As China builds biotech sector, cash floods U.S. startups
RE
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on ROCHE HOLDING LTD. 
ROCHE HOLDING LTD. - 2016
An opportunity over the medium term?
BUY
ROCHE HOLDING LTD. - 2016
A medium term support level to take advantage of
BUY
More Strategies
Latest Tweets
09/24Salute to Heroes: Paramedics Conor Roche and Daniel Ludwig save disabled man .. 
09/24Novartis, Bayer consider appeal as court says Avastin can be used in AMD: Eng.. 
09/24Roches Tecentriq in combination with pemetrexed and platinumbased chemotherap..
1
09/24Another Precision Step for Roche as Ignyta Drug Heads to Regulators: There wa.. 
09/24$RHHBY: Roche Hldg announces results for entrectinib which showed that entrec.. 
More tweets
Qtime:214
News from SeekingAlpha
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
09/24Roche's Tecentriq + chemo improved progression-free survival in late-stage st.. 
09/24Roche announces global availability of FoundationOne Liquid 
09/22STOCKS TO WATCH : Calling Up Animal Spirits 
09/21Key events next week - healthcare 
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 259  CHF
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-4.60%211 501
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
MERCK AND COMPANY26.36%189 092
AMGEN17.94%132 756